Europe Atopic Dermatitis Drugs Market Size & Outlook
Europe atopic dermatitis drugs market, 2018-2030 (US$M)
Related Markets
Europe atopic dermatitis drugs market highlights
- The Europe atopic dermatitis drugs market generated a revenue of USD 4,719.1 million in 2024.
- The market is expected to grow at a CAGR of 9.2% from 2025 to 2030.
- In terms of segment, biologics was the largest revenue generating drug class in 2024.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 4,719.1 million |
| Market revenue in 2030 | USD 8,067.5 million |
| Growth rate | 9.2% (CAGR from 2025 to 2030) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.8% of the global atopic dermatitis drugs market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,565.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe atopic dermatitis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 45.06% in 2024. Horizon Databook has segmented the Europe atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of atopic dermatitis, coupled with growing investments in atopic dermatitis research initiatives, is expected to drive Europe’s market. However, the current European economic crisis and presence of uneven reimbursement policies act as market restraints.
The prevalence of atopic dermatitis is much higher in Northern Europe than Eastern Europe. For instance, the prevalence of atopic dermatitis in adolescents in Denmark, Finland, Bulgaria, and Hungary is over 15%. Owing to the prevalence being higher than the global average of 7.3%, the demand for treatment is higher in Europe.
As per the British Journal of Dermatology in 2020, the first treatment preference of dermatologists in this region was phototherapy, with an 84.7% prescription rate. This was followed by use of systemic therapies, such as oral corticosteroids.
Reasons to subscribe to Europe atopic dermatitis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe atopic dermatitis drugs market databook
-
Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe atopic dermatitis drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe atopic dermatitis drugs market size, by country, 2018-2030 (US$M)
Europe Atopic Dermatitis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
